Trial Profile

Phase I Trial of Z-Endoxifen in Adults With Refractory Hormone Receptor-Positive Breast Cancer, Desmoid Tumors, Gynecologic Tumors, or Other Hormone Receptor-Positive Solid Tumors

Status: Active, no longer recruiting

Phase of Trial: Phase I

Latest Information Update: 25 Sep 2024

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Endoxifen (Primary)
Indications Advanced breast cancer; Colorectal cancer; Endometrial cancer; Fallopian tube cancer; Fibroma; Gynaecological cancer; HER2 positive breast cancer; Male breast cancer; Non-small cell lung cancer; Ovarian cancer; Peritoneal cancer; Prostate cancer; Solid tumours; Uterine cancer
Focus Adverse reactions

Most Recent Events

29 May 2024 Planned End Date changed from 1 Jun 2024 to 1 Jun 2026.
13 Jun 2023 Planned End Date changed from 1 Jun 2023 to 1 Jun 2024.
15 Jun 2022 Planned End Date changed from 1 Jun 2022 to 1 Jun 2023.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com